Optimizing the Use of Checkpoint Inhibitors in NSCLC
Meeting Series
Meeting Series

Optimizing the Use of Checkpoint Inhibitors in NSCLC

Rallying the Troops

Not a member of My prIME? Join now for instant access.

This live meeting series is designed specifically for clinicians who treat and manage veterans with lung cancer. The content will provide an update on the latest information on immunotherapy, patient identification, adverse event management, and treatment selection. The update will be followed by case presentation and discussion.

CME

CME

1.0 AMA PRA Category 1 Credit

This meeting series has ended.

5 min Welcome and introduction
5 min Oncology Guru™: What do you know about checkpoint inhibition in lung cancer?
5 min Checkpoint inhibitors: Mechanisms of action
18 min Using checkpoint inhibitors to treat lung cancer
7 min Immune-related adverse events: Identification and management
8 min Incorporating checkpoint inhibitors into treatment of non-small cell lung cancer (NSCLC): An interactive exercise
5 min Assessing what you have learned from this activity: Have you increased your “guru” status?
7 min prIME Points™, questions & answers, conclusion
Adjourn

Chairs

  • Corey Carter, MDJohn P. Murtha Cancer Center
    Walter Reed National Military Medical Center
    National Cancer Institute/National Institutes of Health
    Bethesda, Maryland, United States
  • Naiyer Rizvi, MDNew York-Presbyterian Hospital
    Columbia University Medical Center
    New York, New York, United States

Presenting Faculty

  • Hossein Borghaei, DOFox Chase Cancer Center
    Philadelphia, Pennsylvania, United States
  • Christina Brzezniak, MDWalter Reed National Military Medical Center
    Bethesda, Maryland, United States
  • Corey Carter, MDJohn P. Murtha Cancer Center
    Walter Reed National Military Medical Center
    National Cancer Institute/National Institutes of Health
    Bethesda, Maryland, United States
  • Leora Horn, MDVanderbilt-Ingram Cancer Center
    Nashville, Tennessee, United States
  • Karen Reckamp, MDCity of Hope
    Duarte, California, United States
  • Naiyer Rizvi, MDNew York-Presbyterian Hospital
    Columbia University Medical Center
    New York, New York, United States

This activity is designed to meet the needs of medical, surgical, and radiation oncologists, as well as advanced practitioners and mid-level providers who treat/manage patients in the VA system or in the VA Choice programs with lung cancer.

After successful completion of this educational activity, participants should be able to:

  • Discuss the mechanisms of action of checkpoint inhibitors used in the treatment of lung cancer
  • Design optimal strategies for the treatment of NSCLC that incorporate the use of checkpoint inhibitors
  • Select the appropriate strategy for managing/mitigating side effects

This educational activity is supported by grants from AstraZeneca and Merck and Co, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Optimizing the Use of Checkpoint Inhibitors in NSCLC - prIME Oncology

prIME Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.